Literature DB >> 20625647

Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Vera S G Ferreira1, Ricardo B Pernambuco, Edmundo P Lopes, Clarice N Morais, Marbiana C Rodrigues, Maria Juliana Arruda, Lidiane Moura E Silva, Lucio Vilar.   

Abstract

OBJECTIVE: To evaluate the frequency of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (DM2) and to describe its risk factors. SUBJECTS AND METHODS: Blood samples of 78 patients were collected for assessment of glycemic and lipid profile, liver enzymes, TNF-alpha and HOMA-IR. The diagnosis of NAFLD was established by ultrasound.
RESULTS: NAFLD was observed in 42% of patients who had greater BMI (p < 0.001), and frequency of hypertension (p < 0.001). Metabolic syndrome was more frequent in those with NAFLD (p = 0.019). The levels of aspartate, alanine aminotransferase, gamma-glutamyl transpeptidase, uric acid, TNF-alpha, insulin and HOMA-IR were significantly higher in patients with NAFLD than those without NAFLD.
CONCLUSION: Almost half of patients with DM2 were found to have NAFLD, and they have more elevated BMI, as well as higher levels of aminotransferases, gamma-GT, uric acid, TNF-alpha, insulin and HOMA-IR than subjects without NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625647     DOI: 10.1590/s0004-27302010000400004

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  12 in total

1.  Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.

Authors:  Laura G Sanchez-Lozada; Ana Andres-Hernando; Fernando E Garcia-Arroyo; Christina Cicerchi; Nanxing Li; Masanari Kuwabara; Carlos A Roncal-Jimenez; Richard J Johnson; Miguel A Lanaspa
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

Review 2.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

Review 3.  What should we recommend to our patients with NAFLD regarding alcohol use?

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2012-07       Impact factor: 10.864

4.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

5.  Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis.

Authors:  Isabella Ramos de Oliveira Liberato; Edmundo Pessoa de Almeida Lopes; Maria Alina Gomes de Mattos Cavalcante; Tiago Costa Pinto; Izolda Fernades Moura; Luiz Loureiro Júnior
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 6.  Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?

Authors:  Mohamed H Ahmed; Nazik Elmalaika Os Husain; Ahmed O Almobarak
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar

7.  Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver.

Authors:  Miguel A Lanaspa; Laura G Sanchez-Lozada; Christina Cicerchi; Nanxing Li; Carlos A Roncal-Jimenez; Takuji Ishimoto; Myphuong Le; Gabriela E Garcia; Jeffrey B Thomas; Christopher J Rivard; Ana Andres-Hernando; Brandi Hunter; George Schreiner; Bernardo Rodriguez-Iturbe; Yuri Y Sautin; Richard J Johnson
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

Review 8.  The Wide and Complex Field of NAFLD Biomarker Research: Trends.

Authors:  Erika Wichro; Tanja Macheiner; Jasmin Schmid; Barbara Kavsek; Karine Sargsyan
Journal:  ISRN Hepatol       Date:  2014-04-28

Review 9.  Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System.

Authors:  Mohamed H Ahmed; Sufian K Noor; Sarra O Bushara; Nazik Elmalaika Husain; Wadie M Elmadhoun; Ibrahim A Ginawi; Meissa M Osman; Abdalhafeez O Mahmoud; Ahmed O Almobarak
Journal:  Gastroenterology Res       Date:  2017-10-26

Review 10.  Nonalcoholic fatty liver disease: Diagnostic biomarkers.

Authors:  Fatemeh Hadizadeh; Elham Faghihimani; Peyman Adibi
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.